Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDF
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
NPS RADAR August 2010NPS RADAR August 2010
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR August 2010 Professional publication - NPS RADAR - Complete issue | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Sitagliptin, vildagliptin and saxagliptin — dipeptidyl peptidase-4 inhibitors (‘gliptins’) for add-on therapy in type 2 diabetes mellitus Professional publication - NPS RADAR - Review | DPP-4 inhibitors (‘gliptins’) are a recently introduced class of oral drugs for improving glycaemic control in patients with type 2 diabetes mellitus. They are approved as add-on therapy in combination with either metformin or a sulfonylurea in patients poorly controlled with metformin, a sulfonylurea or a thiazolidinedione. The RADAR article on gliptins has been updated to reflect the listing of another gliptin. Saxagliptin was added to the PBS on 1 June 2011. |
| Immediate-release pramipexole (Sifrol) and extended-release pramipexole (Sifrol ER) for Parkinson’s disease Professional publication - NPS RADAR - Review | Pramipexole is a non-ergot dopamine agonist for treating early Parkinson’s disease. Sleep attacks and compulsive behaviour have been reported with pramipexole and other dopamine agonists |
| PBS listing of extended-release pramipexole (Sifrol ER) for Parkinson’s disease Professional publication - NPS RADAR - Brief item | An extended-release formulation of pramipexole (Sifrol ER) has been listed on the PBS for treating Parkinson’s disease. |
| Paracetamol with caffeine (Panadol Extra) available over the counter from pharmacies Professional publication - NPS RADAR - Brief item | Paracetamol with caffeine (Panadol Extra) available over the counter from pharmacies |
| Adrenaline autoinjector (Anapen) for acute allergic anaphylaxis Professional publication - NPS RADAR - Review | Anapen is a new autoinjector for the emergency treatment of anaphylaxis. It has a substantially different administration technique to that of EpiPen. |
| Exenatide (Byetta): first in another new class of diabetes drugs Professional publication - NPS RADAR - Brief item | Exenatide is an injectable drug in the new class of incretin mimetics, PBS listed from 1 August 2010 for type 2 diabetes. |
| Anakinra (Kineret) to be deleted from the PBS Professional publication - NPS RADAR - Brief item | On 1 December 2010, anakinra (Kineret) will be deleted from the Schedule of Pharmaceutical Benefits. Listings for other biological disease-modifying anti-rheumatic drugs (bDMARDs) will remain unchanged, and anakinra will continue to be available as a private prescription. |
| Anaphylaxis management plan Professional publication - NPS RADAR - Web only item | Anaphylaxis management plans and Adrenaline autoinjector (Anapen) for acute allergic anaphylaxis |
| ASCIA guidelines for prescribing an adrenaline autoinjector Professional publication - NPS RADAR - Web only item | ASCIA guidelines for prescribing an adrenaline autoinjector |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2010-08-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
